Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The remarkable progress on engineering and clinical development of therapeutic antibodies in the last forty years, after the seminal work by Köhler and Milstein in 1975, have led to the approval by the United States Food and Drug Administration (FDA) of 21 antibodies for cancer immunotherapy. We review here these approved antibodies, with emphasis on the methods used for their discovery, engineering, and optimization for therapeutic settings. These methods include antibody engineering via chimerization and humanization of non-human antibodies, as well as selection and further optimization of fully human antibodies isolated from human antibody phage-displayed libraries, and immunization of transgenic mice capable of generating human antibodies. These technology platforms have progressively led to the development of therapeutic antibodies with higher human content and, thus, less immunogenicity. We also discuss the genetic engineering approaches that have allowed isotype switching and Fc modifications to modulate effector functions and bioavailability (half-life), which together with the technologies for engineering the Fv fragment have been pivotal in generating more efficacious and better tolerated therapeutic antibodies to treat cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Somatic generation of antibody diversity
Tonegawa, S. (1983) · Nature · doi:10.1038/302575a0 · Cited by 4,005
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“Since antibody effector functions such as ADCC have been considered important mechanisms of action (MOA) for cancer immunotherapy, human IgG1 was the isotype of choice for therapeutic development of the first approved oncology therapeutic antibodies (15).”
BackgroundIgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · cited 2×
“LEC13 Hamster ovary (CHO variant) Deficient in GDP-mannose 4,6 dehydratase (GMD) (157)”
BackgroundShinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · cited 2×
“YB2/0 Rat hybridoma (B lymphoblast) Low natural FUT8 expression levels (127, 134, 154)”
BackgroundReplacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406 · cited 5×
“Thus, to further increase the human content of therapeutic antibodies, in the second half of the 1980s Winter’s group at the Medical Research Council (11) showed that by grafting the CDRs from an antibody into FRs of another antibody, the specificity and affinity of CDR donor antibody can be transferred to the antibod…”
BackgroundInfluentialMusolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764 · cited 2×
“CHO Hamster ovary Overexpression of GnTIII (GlycoMab Technology) (161, 162)”
Background
Cited by
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
Candelaria, P. V., Leoh, L. S., Penichet, M. L., & Daniels-Wells, T. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.607692 · Cited by 268
Self-citationDLAB-deep learning methods for structure-based virtual screening of antibodies
Schneider, C., Buchanan, A., Taddese, B., & Deane, C. M. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btab660 · Cited by 102
Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800896 · Cited by 82
Goydel, R. S., Weber, J., Peng, H., Qi, J., Soden, J., Freeth, J., Park, H., & Rader, C. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012791 · Cited by 34
“mAbs are widely used as cancer therapeutics with 30 antibody-based cancer therapies FDA(4)-approved and marketed (1).”
Metadata
- Authors
- Almagro, J. C., Daniels-Wells, T. R., Perez-Tapia, S. M., & Penichet, M. L.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-01-04
- Volume
- 8
- Pages
- 1751-1751
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2782220244
- Cited by
- 157
- References
- 20
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. https://app.cochat.ai/papers/10.3389/fimmu.2017.01751
- The paper
- Almagro, J. C., Daniels-Wells, T. R., Perez-Tapia, S. M., & Penichet, M. L. (2018). Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2017.01751
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.